Scholarlink

Purpose <p>Targeted radionuclide therapy (TRT), specifically peptide receptor radionuclide therapy (PRRT) with [<sup>177</sup>Lu]Lu-DOTA-TATE is an established treatment for somatostatin receptor–expressing neuroendocrine tumors across different grades; however, its efficacy in other tumors expressing somatostatin receptors remains less defined. This study aimed to evaluate the safety and efficacy of PRRT with [<sup>177</sup>Lu]Lu-DOTA-TATE in patients with medullary thyroid cancer (MTC) who presented with progressive recurrence or metastases refractory to standard therapies.</p> Methods <p>Ten patients with MTC (3 females, 7 males; mean age 45.0 ± 13.0 years) underwent slow intravenous injection of [<sup>177</sup>Lu]Lu-DOTA-TATE combined with lysine-arginine co-infusion in 2000 mL normal saline. Each patient received a median of 4 cycles (IQR: 3.0–5.3) with a mean activity of 5.5 ± 1.5 GBq per cycle. Post-treatment imaging and serial measurements of calcitonin and carcinoembryonic antigen (CEA) were performed. Hematologic and biochemical toxicities were assessed according to CTCAE criteria.</p> Results <p>Calcitonin levels showed a marked numerical decline from 6452.6 ± 8565.7(median:1897.5, interquartile range:127-12993.8) pg/mL to 540.9 ± 632.1 (390, IQR;141.8-723.3) pg/mL, although this change did not reach conventional statistical significance (<i>P</i> = 0.093), while CEA levels decreased significantly from 119.0 ± 186.2 (40, IQR:10.9–199) ng/ml ng/mL to 56.1 ± 67.9 (22, deIQR:5.7-112.3) ng/mL (<i>P</i> = 0.017). Based on calcitonin levels, biochemical response, stable disease, and progression were observed in 4, 4, and 2 patients, respectively; in contrast, CEA showed a biochemical response in 3 patients, with the remaining 7 demonstrating stable disease and no cases of biochemical progression. The median percentage reductions from baseline were clinically meaningful, reaching − 39.3% for calcitonin and − 25.8% for CEA. On imaging assessment, the best overall response comprised partial response in 4 patients, stable disease in 4 patients, and progressive disease in 2 patients. Only grade 1 hematologic toxicity was observed, with no hepatic or renal toxicity detected. White blood cell counts declined from 6144.4 ± 2362.3/µL to 4927.8 ± 1635.3/µL (<i>P</i> = 0.027), while other hematologic, renal, and hepatic parameters remained stable.</p> Conclusion <p>[<sup>177</sup>Lu]Lu -DOTA-TATE PRRT was safe and effective in controlling disease progression and reducing tumor markers in MTC patients unresponsive to conventional therapy, supporting further evaluation in larger studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Outcomes of 177Lu-DOTATATE Targeted Therapy in Patients with Medullary Thyroid Cancer: A Case Series of 10 Patients

  • 期刊论文

  • 发表日期：

    2026年2月20日

查看全文
  • Farzanehfar Saeed,
  • Reza Hossein,
  • Salehi Yalda,
  • Ghasri Mohammad Reza,
  • Abbasi Mehrshad

摘要

Purpose

Targeted radionuclide therapy (TRT), specifically peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE is an established treatment for somatostatin receptor–expressing neuroendocrine tumors across different grades; however, its efficacy in other tumors expressing somatostatin receptors remains less defined. This study aimed to evaluate the safety and efficacy of PRRT with [177Lu]Lu-DOTA-TATE in patients with medullary thyroid cancer (MTC) who presented with progressive recurrence or metastases refractory to standard therapies.

Methods

Ten patients with MTC (3 females, 7 males; mean age 45.0 ± 13.0 years) underwent slow intravenous injection of [177Lu]Lu-DOTA-TATE combined with lysine-arginine co-infusion in 2000 mL normal saline. Each patient received a median of 4 cycles (IQR: 3.0–5.3) with a mean activity of 5.5 ± 1.5 GBq per cycle. Post-treatment imaging and serial measurements of calcitonin and carcinoembryonic antigen (CEA) were performed. Hematologic and biochemical toxicities were assessed according to CTCAE criteria.

Results

Calcitonin levels showed a marked numerical decline from 6452.6 ± 8565.7(median:1897.5, interquartile range:127-12993.8) pg/mL to 540.9 ± 632.1 (390, IQR;141.8-723.3) pg/mL, although this change did not reach conventional statistical significance (P = 0.093), while CEA levels decreased significantly from 119.0 ± 186.2 (40, IQR:10.9–199) ng/ml ng/mL to 56.1 ± 67.9 (22, deIQR:5.7-112.3) ng/mL (P = 0.017). Based on calcitonin levels, biochemical response, stable disease, and progression were observed in 4, 4, and 2 patients, respectively; in contrast, CEA showed a biochemical response in 3 patients, with the remaining 7 demonstrating stable disease and no cases of biochemical progression. The median percentage reductions from baseline were clinically meaningful, reaching − 39.3% for calcitonin and − 25.8% for CEA. On imaging assessment, the best overall response comprised partial response in 4 patients, stable disease in 4 patients, and progressive disease in 2 patients. Only grade 1 hematologic toxicity was observed, with no hepatic or renal toxicity detected. White blood cell counts declined from 6144.4 ± 2362.3/µL to 4927.8 ± 1635.3/µL (P = 0.027), while other hematologic, renal, and hepatic parameters remained stable.

Conclusion

[177Lu]Lu -DOTA-TATE PRRT was safe and effective in controlling disease progression and reducing tumor markers in MTC patients unresponsive to conventional therapy, supporting further evaluation in larger studies.